Ambulatory Detoxification in Alcohol Use Disorder and Opioid Use Disorder

Overview

Journal Ment Health Clin

Specialty Psychiatry

Date 2020 Nov 23

PMID 33224688

Authors

Troy A Moore

Affiliations

Soon will be listed here.

Abstract

Ambulatory detoxification in alcohol use disorder and opioid use disorder is an important component in the management of patients experiencing withdrawal symptoms from alcohol or opioids. The goal of withdrawal management is ultimately to provide each patient with comfort and safety. Having the knowledge of the possible signs and symptoms of intoxication and withdrawal assists providers to institute the most appropriate treatment protocol and setting for the patient. Pharmacists play a vital role in choosing appropriate therapeutic management options for common or complex clinical situations involving ambulatory detoxification from alcohol and opioids. Ambulatory detoxification serves as an appealing option to many patients and helps save the limited inpatient resources that many institutions have for those patients with more severe withdrawal presentations.

References

Stuppaeck C, Pycha R, Miller C, Whitworth A, Oberbauer H, Fleischhacker W . Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol. 1992; 27(2):153-8. View

Mattes J . Treating ADHD in Prison: Focus on Alpha-2 Agonists (Clonidine and Guanfacine). J Am Acad Psychiatry Law. 2016; 44(2):151-7. View

Peppers M . Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease. Pharmacotherapy. 1996; 16(1):49-57. View

Lin S, Strang J, Su L, Tsai C, Hu W . Double-blind randomised controlled trial of lofexidine versus clonidine in the treatment of heroin withdrawal. Drug Alcohol Depend. 1997; 48(2):127-33. DOI: 10.1016/s0376-8716(97)00116-6. View

San L, Cami J, Peri J, Mata R, Porta M . Efficacy of clonidine, guanfacine and methadone in the rapid detoxification of heroin addicts: a controlled clinical trial. Br J Addict. 1990; 85(1):141-7. DOI: 10.1111/j.1360-0443.1990.tb00634.x. View

Sullivan J, Sykora K, Schneiderman J, Naranjo C, Sellers E . Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989; 84(11):1353-7. DOI: 10.1111/j.1360-0443.1989.tb00737.x. View

Malcolm R, Ballenger J, Sturgis E, Anton R . Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry. 1989; 146(5):617-21. DOI: 10.1176/ajp.146.5.617. View

Kampman K, Jarvis M . American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. J Addict Med. 2015; 9(5):358-67. PMC: 4605275. DOI: 10.1097/ADM.0000000000000166. View

Wilson M, HARING O, Lewin A, Bedsole G, STEPANSKY W, Fillingim J . Comparison of guanfacine versus clonidine for efficacy, safety and occurrence of withdrawal syndrome in step-2 treatment of mild to moderate essential hypertension. Am J Cardiol. 1986; 57(9):43E-49E. DOI: 10.1016/0002-9149(86)90723-x. View

10.

. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997; 278(2):144-51. DOI: 10.1001/jama.278.2.144. View

11.

Myrick H, Malcolm R, Randall P, Boyle E, Anton R, Becker H . A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009; 33(9):1582-8. PMC: 2769515. DOI: 10.1111/j.1530-0277.2009.00986.x. View

12.

. Guanfacine: a second generation alpha 2-adrenergic blocker. Am J Med Sci. 1990; 299(1):73-6. DOI: 10.1097/00000441-199001000-00016. View

13.

Wesson D, Ling W . The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003; 35(2):253-9. DOI: 10.1080/02791072.2003.10400007. View

14.

Carnwath T, Hardman J . Randomised double-blind comparison of lofexidine and clonidine in the out-patient treatment of opiate withdrawal. Drug Alcohol Depend. 1998; 50(3):251-4. DOI: 10.1016/s0376-8716(98)00040-4. View

15.

Bickel W, Stitzer M, Bigelow G, Liebson I, Jasinski D, Johnson R . A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988; 43(1):72-8. DOI: 10.1038/clpt.1988.13. View

16.

Jauhar P, Anderson J . Is daily single dosage of diazepam as effective as chlordiazepoxide in divided doses in alcohol withdrawal--a pilot study. Alcohol Alcohol. 2000; 35(2):212-4. DOI: 10.1093/alcalc/35.2.212. View

17.

Reoux J, Saxon A, Malte C, Baer J, Sloan K . Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001; 25(9):1324-9. View

18.

Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W . A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2012; 7(1):33-8. PMC: 3567310. DOI: 10.1097/ADM.0b013e318277e92e. View

19.

Hayashida M, Alterman A, McLellan A, OBrien C, Purtill J, Volpicelli J . Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. N Engl J Med. 1989; 320(6):358-65. DOI: 10.1056/NEJM198902093200605. View

20.

Diamant K, Fischer G, Schneider C, Lenzinger E, Pezawas L, Schindler S . Outpatient opiate detoxification treatment with buprenorphine. Preliminary investigation. Eur Addict Res. 1998; 4(4):198-202. DOI: 10.1159/000018953. View